Osteoporosis Drugs Market Size, Share, Trends, Growth and Forecast 2032

Table Of Content

Methodology

Free Analysis

Osteoporosis is a bone disease, which may be due to lower than normal peak bone mass and greater than the normal bone loss. Osteoporosis may also occur due to a number of diseases or treatments such as anorexia, hyperthyroidism, alcoholism, surgical removal of the ovaries, and kidney disease. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps.  Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of medicine for osteoporosis, including Zoledronic Acid (Reclast or Zometa) Fosamax, Actonel, Boniva and others.

The major driving factor for the global osteoporosis market is rapidly growing the geriatric population of the world coupled with changing lifestyle is impinging bone health. Furthermore, increasing the prevalence of osteoporosis in postmenopausal women and increasing investment in drug discovery and development is further expected to fuel the market growth in the years to come. Prevalence of osteoporosis is more common with age. Around 15% of white people in their 50s and 70% of those over 80 are affected by osteoporosis diseases. However, there are several side effects of osteoporosis drugs such as irritable bowel syndrome, heartburn, nausea, and ulcers in the stomach. Thus, side effects of osteoporosis drugs are expected to hamper the market growth over the next few years. Nevertheless, increasing investment in R&D for advanced development of new drugs and classes are expected open up new growth avenues within the forecast period.

The osteoporosis drugs market is segmented on the basis of different drug classes such as bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs).  Osteoporosis drugs market was dominated by the bisphosphonates segment, which accounted for significant revenue share in 2015. Bisphosphonates are commonly prescribed the drug for treatment and prevention of osteoporosis disease. Thus, this segment is expected to show strong growth in the near future. Tele-monitoring is another growing segment of this market. Parathyroid hormone therapy (PTH) was another growing segment of this market. Parathyroid hormone therapy (PTH) was another key segment and it expected to witness significant growth in the near future. Development of new drug classes such as PTH and RANK ligand inhibitors are projected to fuel the growth of osteoporosis drug market over the forecast period. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are awaiting the approval and may contribute to driving the market growth in the years to come.

Based on gender, the market can be segmented into male and female. Osteoporosis is more common in female than male. The female segment accounted for the largest share in 2015. Increasing the prevalence of osteoporosis in postmenopausal women is driving the growth of the market. There are wide discrepancies between the incidence rate in women and men. Moreover, about 90% of the hip fractures occur in people over 50 years old.

North America was the largest regional market led by the U.S. and is projected to witness the highest growth within the forecast period owing to high investments in the healthcare industry, surging R&D initiatives and accessibility to the excellent infrastructure. Asia Pacific osteoporosis drugs market is expected to be the fastest-growing region in the years to come. Growth in this region will be mainly driven by factors such as rising aged population and increasing patient’s awareness pertaining to bone health. Latin America and the Middle East & Africa are also expected to experience significant growth of osteoporosis market in the years to come.

Some of the key participants in osteoporosis drug market are Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.  Major players are implementing sustainability strategies including product expansions, new product development and merger & acquisitions to gain the advantage over the competitors. For instance, drug maker Actavis Inc. agreed to acquire Warner Chilcott PLC for about USD5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specialty pharmaceutical brands—and shrinking its tax burden in 2013. Pipeline drugs of Merck and Pfizer cathepsin and aprela respectively are projected to provide the growth platform for these respective companies.